|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_on1032303152 |
| 003 |
OCoLC |
| 005 |
20231120010253.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
180425s2018 mau o 000 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d OPELS
|d N$T
|d YDX
|d OHS
|d OCLCQ
|d OCLCO
|d UAB
|d OCLCO
|d UPM
|d D6H
|d OCLCF
|d OCLCO
|d NLE
|d INT
|d UKMGB
|d OCLCQ
|d UKAHL
|d DKU
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 016 |
7 |
|
|a 018849326
|2 Uk
|
| 019 |
|
|
|a 1032670746
|a 1032707915
|a 1033526198
|a 1033549448
|
| 020 |
|
|
|a 9780128143414
|q (electronic bk.)
|
| 020 |
|
|
|a 012814341X
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128143407
|q (print)
|
| 020 |
|
|
|z 0128143401
|
| 035 |
|
|
|a (OCoLC)1032303152
|z (OCoLC)1032670746
|z (OCoLC)1032707915
|z (OCoLC)1033526198
|z (OCoLC)1033549448
|
| 050 |
|
4 |
|a QP551
|
| 072 |
|
7 |
|a SCI
|x 007000
|2 bisacsh
|
| 072 |
|
7 |
|a PSF
|2 bicssc
|
| 072 |
|
7 |
|a PSD
|2 bicssc
|
| 082 |
0 |
4 |
|a 572/.6
|2 23
|
| 245 |
0 |
0 |
|a Therapeutic proteins and peptides /
|c edited by Rossen Donev.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press is an imprint of Elsevier,
|c 2018.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in protein chemistry and structural biology ;
|v volume 112
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed April 27, 2018).
|
| 505 |
0 |
|
|a Intro; Title page; Table of Contents; Copyright; Contributors; Preface; Chapter One: Rational Design of Liquid Formulations of Proteins; Abstract; 1 Chemical Instability; 2 Conformational Instability; 3 Colloidal Stability; 4 Interfacial Instability; 5 Conclusions; Chapter Two: Therapeutic Monoclonal Antibodies Delivery for the Glioblastoma Treatment; Abstract; 1 Introduction; 2 Glioblastoma Pathophysiology; 3 Diagnosis of Glioblastoma; 4 Treatment of Glioblastoma; 5 Nanotechnology-Based Drug Delivery Systems Carrying Antibodies to Overcome Current Therapy of Glioblastoma; 6 Conclusion
|
| 505 |
8 |
|
|a AcknowledgmentsChapter Three: Dynamical Behavior of Somatostatin-14 and Its Cyclic Analogues as Analyzed in Bulk and on Plasmonic Silver Nanoparticles; Abstract; 1 Introduction; 2 Results and Discussion; 3 Concluding Remarks; 4 Material and Methods; Acknowledgments; Chapter Four: Transglutaminase and Sialyltransferase Enzymatic Approaches for Polymer Conjugation to Proteins; Abstract; 1 Polymer Conjugation to Proteins; 2 Enzymes as Tools for Polymer Conjugation to Proteins; 3 Discussion and Outlook; Acknowledgments
|
| 505 |
8 |
|
|a Chapter Five: Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic PayloadsAbstract; 1 Recombinant Antibodies and Market Size; 2 Structure and Antibody Function; 3 Antibody Fragments and Single-Domain Antibodies; 4 Conjugation Methods for Antibodies; 5 Chemical Modification of Antibody Fragments; 6 Antibody Fragments for Oncology and CNS Applications; 7 Conclusions; Acknowledgments; Chapter Six: Smart Cell-Penetrating Peptide-Based Techniques for Intracellular Delivery of Therapeutic Macromolecules; Abstract; 1 Introduction; 2 An Overview of CPPs
|
| 505 |
8 |
|
|a 3 Smart CPP-Based, Prodrug Like Techniques4 CPP-Shielding Strategy; 5 CPP-Activating Strategy; 6 Perspective; Acknowledgments; Conflict of Interest; Chapter Seven: In Silico Tools and Databases for Designing Peptide-Based Vaccine and Drugs; Abstract; 1 Introduction; 2 Therapeutic Peptide Repositories; 3 In Silico Tools in Peptide-Based Vaccine Designing; 4 In Silico Tools for Adjuvant Designing; 5 In Silico Tools for Peptide-Based Drug Development; 6 Discussion; 7 Conclusion; Chapter Eight: Protein and Peptides for Elderly Health; Abstract; 1 Introduction
|
| 505 |
8 |
|
|a 2 Protein Recommendation for Elderly Health3 Protein/Peptide and Elderly Disease; 4 Summary; Chapter Nine: Peptide Derivatives of Erythropoietin in the Treatment of Neuroinflammation and Neurodegeneration; Abstract; 1 Peptide Drugs; 2 Strategies to Improve the Pharmacokinetic Properties of Peptide Drugs; 3 Peptide Drug Discovery; 4 Erythropoietin; 5 Chemically Modified and Nonerythropoietic Erythropoietin Analogs; 6 Growth Factor Mimetic Peptide Drugs; 7 Erythropoietin Mimetic Peptides; 8 Future Perspectives and Conclusion
|
| 650 |
|
0 |
|a Proteins.
|
| 650 |
|
0 |
|a Peptide drugs.
|
| 650 |
|
2 |
|a Peptides
|0 (DNLM)D010455
|
| 650 |
|
2 |
|a Proteins
|0 (DNLM)D011506
|
| 650 |
|
6 |
|a Prot�eines.
|0 (CaQQLa)201-0008150
|
| 650 |
|
6 |
|a M�edicaments peptidiques.
|0 (CaQQLa)201-0263772
|
| 650 |
|
7 |
|a protein.
|2 aat
|0 (CStmoGRI)aat300206575
|
| 650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Biochemistry.
|2 bisacsh
|
| 650 |
|
7 |
|a Peptide drugs
|2 fast
|0 (OCoLC)fst01057556
|
| 650 |
|
7 |
|a Proteins
|2 fast
|0 (OCoLC)fst01079711
|
| 700 |
1 |
|
|a Donev, Rossen,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Therapeutic proteins and peptides.
|d Cambridge, MA : Academic Press is an imprint of Elsevier, 2018
|z 0128143401
|z 9780128143407
|w (OCoLC)1015857959
|
| 830 |
|
0 |
|a Advances in protein chemistry and structural biology ;
|v v. 112.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/18761623/112
|z Texto completo
|
